Drug Price Increases Have Slowed, but New Analysis Shows Launch Prices Pushing Costs into Orbit
The U.S. drug pricing system is complicated. But at its core is the premise that we as Americans willingly grant exclusive patents to drug manufacturers to entice them to bring new, hopefully-innovative, brand-name drugs into the market. It should come as no surprise that this profit-incentive yields new drugs with growing costs to the overall healthcare system.
